The Kampmann Lab, led by Dr. Martin Kampmann, develops and applies innovative technologies to understand cellular and molecular mechanisms of aging-associated neurodegenerative diseases, and to discover new therapeutic strategies. A major focus of our research is Alzheimer’s disease and related dementias. We have pioneered a CRISPR-based functional genomics platform in human iPSC-derived neurons and glia, which enables genome-wide modifier screens of disease-relevant cell biology in patient-derived cells. We have also developed cell-type specific CRISPR screening approaches for mouse models of disease. Supported by the Kissick Family Foundation, our current project investigates how genetic risk variants associated with sporadic frontotemporal dementia act in specific cell types, with the ultimate goal to uncover new therapeutic strategies.